Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
XTL Biopharmaceuticals Ltd ADR (XTLB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: XTLB (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 8.81% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.22M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) - | Beta 0.99 | 52 Weeks Range 0.86 - 3.05 | Updated Date 06/29/2025 |
52 Weeks Range 0.86 - 3.05 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -227.72% | Operating Margin (TTM) -200.49% |
Management Effectiveness
Return on Assets (TTM) -24.74% | Return on Equity (TTM) -26.83% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9117987 | Price to Sales(TTM) 22.67 |
Enterprise Value 9117987 | Price to Sales(TTM) 22.67 | ||
Enterprise Value to Revenue 20.22 | Enterprise Value to EBITDA 16.88 | Shares Outstanding 8813850 | Shares Floating 451886180 |
Shares Outstanding 8813850 | Shares Floating 451886180 | ||
Percent Insiders 41.29 | Percent Institutions 2.92 |
Upturn AI SWOT
XTL Biopharmaceuticals Ltd ADR
Company Overview
History and Background
XTL Biopharmaceuticals Ltd ADR (XTLB) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for autoimmune diseases and infectious diseases. Founded in Israel, the company has evolved through various stages of research and development, focusing on antibody-based therapeutics.
Core Business Areas
- Autoimmune Diseases: Development of therapeutic antibodies to treat autoimmune conditions. Their lead candidate is hCDR1, a peptide-based immunotherapy targeting T cells and B cells implicated in autoimmune pathogenesis.
- Infectious Diseases: Research and development of therapies for infectious diseases. Focus on identifying and developing novel antibodies to neutralize viruses or bacteria, and boost the bodyu2019s immune response. Their current infectious diseases focus involves antibody targeting of various infectious disease pathogens.
Leadership and Structure
The leadership team comprises executives with experience in biotechnology, drug development, and finance. The company is structured around research and development, clinical trials, and regulatory affairs, headed by a CEO and supported by various department heads.
Top Products and Market Share
Key Offerings
- hCDR1: hCDR1 is a peptide-based immunotherapy currently in clinical development for the treatment of autoimmune diseases. The market share for the target autoimmune diseases varies based on the specific condition. Competitors include major pharmaceutical companies with approved autoimmune therapies (e.g., Humira, Remicade, Enbrel) and other biotech companies developing novel autoimmune treatments. XTLB does not yet have market share or generate revenue from this candidate since it is in clinical trials.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and the need for constant innovation. Advances in biotechnology, genomics, and immunology are driving the development of novel therapeutics.
Positioning
XTL Biopharmaceuticals is positioned as a clinical-stage biopharmaceutical company focusing on niche therapeutic areas. Their competitive advantage lies in their innovative antibody-based therapeutic platform and their pipeline of promising drug candidates. They are targeting underserved markets within the autoimmune and infectious disease spaces.
Total Addressable Market (TAM)
The global autoimmune disease therapeutics market is estimated to be worth billions of dollars annually. The specific autoimmune diseases XTL Biopharmaceuticals is targeting account for a significant portion of this market. The infectious disease market also represents a multi-billion dollar opportunity. XTLB is positioned to capture a portion of the TAM if hCDR1 or other candidates are approved.
Upturn SWOT Analysis
Strengths
- Proprietary antibody-based therapeutic platform
- Pipeline of promising drug candidates targeting underserved markets
- Experienced management team
- Focus on autoimmune and infectious diseases
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on clinical trial success
- No currently marketed products
- Small market capitalization
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies for drug development and commercialization
- Expansion into new therapeutic areas
- Acquisition by a larger company
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- ABBV
- JNJ
- PFE
- BMY
- LLY
Competitive Landscape
XTLB faces intense competition from established pharmaceutical companies with greater financial and R&D resources. Its success depends on demonstrating superior efficacy and safety with its novel therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been largely driven by progress in its pipeline, specifically its hCDR1 clinical trials. However, due to a lack of commercialized products, financial growth remains limited.
Future Projections: Future growth projections depend on the successful completion of clinical trials and regulatory approval of hCDR1 and other drug candidates. Analyst estimates vary based on the perceived probability of success of the pipeline. Market reception of approved products is another factor.
Recent Initiatives: Recent initiatives include focusing on clinical trial enrollment for hCDR1 and exploring strategic partnerships to advance its pipeline.
Summary
XTL Biopharmaceuticals is a clinical-stage biopharmaceutical firm focusing on novel therapies. It has a promising pipeline in autoimmune and infectious diseases but faces high risks. Clinical trial success is critical for generating revenue. It is positioned to be an innovator but relies on more capital and strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Outlets
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About XTL Biopharmaceuticals Ltd ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2005-09-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 10 | Website https://www.xtlbio.com |
Full time employees 10 | Website https://www.xtlbio.com | ||
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.